Nasdaq
$28.17▼ 0.79%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.78BShares out 2.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
17- 1d agoAfter-hours26.10.24 05:554Ownership#●●●
Immunovant, Inc.
Immunovant, Inc. insider Jay S. Stout filed a Form 4 on October 23, 2026, reporting a change in beneficial ownership of securities effective October 21, 2026. This filing serves as an official disclosure of executive stock holdings to the SEC.…more
$28.17-0.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.9After-hours26.10.10 06:054Ownership
Immunovant, Inc.
Insider Jay S. Stout of Immunovant, Inc. reported a change in beneficial ownership of securities as of October 7, 2026. This filing is a Form 4 statement detailing the executive's equity transaction.…more
$28.17-0.79%vs prev closeView filingShare - 10.9After-hours26.10.10 06:054Ownership
Immunovant, Inc.
Christopher Van Tuyl, an insider at Immunovant, Inc., filed a Form 4 report regarding a change in beneficial ownership of securities as of October 7, 2026. This filing serves as an official disclosure of insider transaction activity.…more
$28.17-0.79%vs prev closeView filingShare
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:00#●●●#●●●
Immunovant to Report Fiscal Q2 2026 Results on November 9
Immunovant announced it will report financial results for the second fiscal quarter ended September 30, 2026, on November 9, 2026. The company will also provide a business update during a scheduled conference call.…more
$28.17-0.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.23Pre-market26.09.23 22:03
●●●●●●●● ●●●●● ●●●●●●
Immunovant has decided to discontinue the development of IMVT-1402 for cutaneous lupus erythematosus after the drug failed to meet its primary endpoint in a clinical trial. The company will now shift its focus toward advancing the drug for other autoimmune conditions.…more
$28.17-0.79%vs prev closeShareBenzinga - 9.23Pre-market26.09.23 20:05
●●●●●●●● ●●●●● ●●●●●●
Immunovant's proof-of-concept trial for IMVT-1402 in cutaneous lupus erythematosus failed to meet its primary endpoint for statistical significance. Consequently, the company has decided to discontinue the development of the drug for this specific indication.…more
$28.17-0.79%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report